| Website | embertx.com |
| Category | BioTech |
| Employees |
| TOTAL | $34M |
| VENTURE FUNDING TOTAL | $34M |
| Series A, 12/11 Third Rock Ventures | $34M |
Ember Therapeutics is a product-focused company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease. Today’s rising epidemic of obesity and Type 2 diabetes coupled with the lack of innovation in the industry’s metabolic disorder treatment pipeline underscores the need for novel, peripherallyacting treatments with improved safety profiles. Ember’s unique approach leverages recent research breakthroughs in brown fat biology to develop a pipeline of proprietary large and small molecules designed to amplify the body’s innate ability to efficiently burn fuels like glucose. Ember’s expertise is also driving the development of the next generation of highly selective insulin sensitizers that have robust anti-diabetic effects, but lack the serious side effects of currently approved insulin sensitizers. Formerly known as Adipothermics, Ember Therapeutics is a private company launched in 2011 by renowned scientific founders, an experienced leadership team and Third Rock Ventures.
